Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019 (H.R. 3396) Gains Additional Support in the U.S. House of Representatives,September 2020

Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019 (H.R. 3396) Re-Introduced in U.S. House of Representatives, June 2019 New co-sponsors: September 2020 This is a similar bill to the ones known in the 112th Congress (2011-2012) as HR 2239, in the 113th Congress (2013-2014) as HR 842, in the 114thCongress (2015-2016) as HR

IFFGD 2020 IBS Patients’ Illness Experience and Unmet Needs Online Survey Open For Response

Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research, medical care and support systems since then. Now in 2020, IFFGD

April is IBS Awareness Month 2020

April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI professionals and organizations who are uniting in our own ways

IFFGD Virtual Advocacy Day Event 2020 Scheduled for July 26-27, 2020

The International Foundation for Gastrointestinal Disorders (IFFGD) has announced the dates for its annual Advocacy Day event which, this year, will be Virtual Advocacy Day on June 27, 2020. This the day each year when a delegation of IFFGD staff, GI researchers, GI disorder-affected people and families gather to advocate with members of the U.S.

U.S. FDA Approves Tenapanor (Ibsrela) for Adults with IBS-C, September 2019

This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the

New Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of IBS– April 2019.

The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology,  health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University